Stock query: Cadila Healthcare faces a vital barrier
The stock is moving sideways in the band between 320 and 35017-05-2020
17-05-2020
CADILA HEALTHCARE LTD. - 532321 - Announcement under Regulation 30 (LODR)-Press Release / Media Release
Zydus Cadila receives tentative approval from USFDA for Droxidopa Capsules, 100 mg, 200 mg, and 300 mg16-05-2020
CADILA HEALTHCARE LTD. - 532321 - Compliance For The Half Year Ended On On March 31, 2020.
Compliance for the half year ended on on March 31, 2020.11-05-2020
CADILA HEALTHCARE LTD. - 532321 - Audited Financial Results
The Company shall approve the audited financial results for the quarter / year ended on March 31, 2020 on or before June 30, 2020.11-05-2020
Zydus Cadila to make indigenous Covid-19 test kits
To start manufacturing of Covid Kavach Elisa' at Ahmedabad facility11-05-2020
CADILA HEALTHCARE LTD. - 532321 - Statement Of Investor Complaints For The Quarter Ended March 2020
No.of Investor complaints pending at the beginning of the quarter No.of Investor complaints received during the quarter No.of Investor complaints disposed of during the quarter No.of Investor complaints unresolved at the end of the quarter 0000 Name of the Signatory :- Dhaval N SoniDesignation :- Company Secretary and Compliance Officer11-05-2020
Zydus Cadila launches generic prostate cancer drug at nearly 70% less price in India
The company's product under the brand name 'Obnyx' is priced at Rs 23,980 per month. The current maximum retail price (MRP) of Enzalutamide drug ranges from Rs 70,000 to 80,000 for a monthly therapy, Zydus Cadila said in a statement.08-05-2020
CADILA HEALTHCARE LTD. - 532321 - Announcement under Regulation 30 (LODR)-Press Release / Media Release
Zydus Cadila Launches Enzalutamide, making Prostate Cancer therapy highly affordable08-05-2020
CADILA HEALTHCARE LTD. - 532321 - Announcement under Regulation 30 (LODR)-Press Release / Media Release
Zydus Cadila receives final approval from USFDA for Deferasirox Tablets for Oral Suspension07-05-2020